Retatrutide Research

Retatrutide in the Published Literature

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-234 cited sources

The short answer

Retatrutide's literature is small but unusually strong: the discovery paper in Cell Metabolism, Phase 2 results in the New England Journal of Medicine and the Lancet, and a Phase 3 programme enrolling more than 5,800 participants reported through Lilly and ClinicalTrials.gov.

Key facts

Discovery
Coskun, Cell Metab 2022 (PMID 35985340)
Phase 2 obesity
Jastreboff, NEJM 2023 (PMID 37366315)
Phase 2 T2D
Rosenstock, Lancet 2023 (PMID 37385280)
Phase 3 enrolment
More than 5,800
Evidence quality
High (randomised, controlled)
Chemical database entry
None findable

An unusual profile for this library

Most compounds here have a large preclinical literature and no controlled human data. Retatrutide has the opposite: relatively few papers, but among them randomised controlled trials published in the New England Journal of Medicine and the Lancet, and a Phase 3 programme of more than 5,800 participants. On evidence quality it is not comparable to anything else in this catalogue.

The three foundational papers

Coskun and colleagues in Cell Metabolism, September 2022, for the discovery and pharmacology. Jastreboff and colleagues in the New England Journal of Medicine, 2023, for Phase 2 in obesity. Rosenstock and colleagues in the Lancet, 2023, for Phase 2 in type 2 diabetes. Almost everything else cites one of these.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Where the Phase 3 data lives

Topline results have been reported through Eli Lilly investor releases, with trials registered on ClinicalTrials.gov. Peer-reviewed publication follows database posting, so for the most recent readouts the investor release is currently the primary accessible source, which is a weaker form of reporting than a full paper.

The gap that is odd

For a compound with this much clinical evidence, retatrutide has no findable PubChem entry. Searches under the name, the development code and the reported CAS all return nothing. The clinical literature is stronger than almost anything else here while the chemical record is weaker, an inversion worth knowing about when checking a certificate of analysis.

How to search it

PubMed under retatrutide and LY3437943. ClinicalTrials.gov for the TRIUMPH registrations, searched directly rather than through secondary sources, because trial status changes. Lilly's investor releases for topline data ahead of publication. Each covers something the others do not.

What none of it establishes

That retatrutide is available or approved. It is investigational everywhere, and the strength of the trial evidence does not change its regulatory position. Research material supplied under this name is not the trial compound.

Frequently asked questions

How strong is retatrutide's evidence?

By the standards of this library, unusually strong. Randomised controlled trials in NEJM and the Lancet, and a Phase 3 programme of over 5,800 participants.

Where are the Phase 3 results published?

Topline data through Eli Lilly investor releases, with trials registered on ClinicalTrials.gov. Peer-reviewed publication follows.

Why is there no PubChem entry?

Not clear, and it is unusual for a compound at this stage. The clinical record is strong while the chemical record is not.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More Retatrutide Research articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.